Double-blind, randomized, placebo controlled trial to study efficacy of pegfilgrastim in reduction of risk of Febrile Neutropenia in early breast cancer Japanese patients

Trial Profile

Double-blind, randomized, placebo controlled trial to study efficacy of pegfilgrastim in reduction of risk of Febrile Neutropenia in early breast cancer Japanese patients

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Oct 2015

At a glance

  • Drugs Pegfilgrastim (Primary) ; Cyclophosphamide; Docetaxel
  • Indications Febrile neutropenia
  • Focus Therapeutic Use
  • Sponsors Kyowa Hakko Kirin
  • Most Recent Events

    • 21 Oct 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top